DelveInsight's "Diabetic Retinopathy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Diabetic Retinopathy , historical and forecasted epidemiology as well as the Diabetic Retinopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Diabetic Retinopathy market report provides current treatment practices, emerging drugs, Diabetic Retinopathy market share of the individual therapies, current and forecasted Diabetic Retinopathy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Diabetic Retinopathy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
The DelveInsight Diabetic Retinopathy market report gives a thorough understanding of the Diabetic Retinopathy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Diabetic Retinopathy .
Treatment
It covers the details of conventional and current medical therapies available in the Diabetic Retinopathy market for the treatment of the condition. It also provides Diabetic Retinopathy treatment algorithms and guidelines in the United States, Europe, and Japan.
The Diabetic Retinopathy epidemiology division provide insights about historical and current Diabetic Retinopathy patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Diabetic Retinopathy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
Country Wise- Diabetic Retinopathy Epidemiology
The epidemiology segment also provides the Diabetic Retinopathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Drug chapter segment of the Diabetic Retinopathy report encloses the detailed analysis of Diabetic Retinopathy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Diabetic Retinopathy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs
The report provides the details of the marketed product available for Diabetic Retinopathy treatment.
Diabetic Retinopathy Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Diabetic Retinopathy treatment.
The Diabetic Retinopathy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Diabetic Retinopathy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Diabetic Retinopathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Diabetic Retinopathy market in 7MM is expected to change in the study period 2017-2030.
Key Findings
This section includes a glimpse of the Diabetic Retinopathy market in 7MM.
The United States Market Outlook
This section provides the total Diabetic Retinopathy market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Diabetic Retinopathy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Diabetic Retinopathy market size and market size by therapies in Japan is also mentioned.
This section focusses on the rate of uptake of the potential drugs recently launched in the Diabetic Retinopathy market or expected to get launched in the market during the study period 2017-2030. The analysis covers Diabetic Retinopathy market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Diabetic Retinopathy key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Diabetic Retinopathy emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SME's opinion working in Diabetic Retinopathy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Diabetic Retinopathy market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Diabetic Retinopathy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Diabetic Retinopathy Report Insights
Diabetic Retinopathy Report Key Strengths
Diabetic Retinopathy Report Assessment
Market Insights:
Epidemiology Insights:
"
1. Key Insights
2. Executive Summary of Diabetic Retinopathy
3. Competitive Intelligence Analysis for Diabetic Retinopathy
4. Diabetic Retinopathy : Market Overview at a Glance
4.1. Diabetic Retinopathy Total Market Share (%) Distribution in 2017
4.2. Diabetic Retinopathy Total Market Share (%) Distribution in 2030
5. Diabetic Retinopathy : Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Diabetic Retinopathy Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Diabetic Retinopathy Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Diabetic Retinopathy Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Diabetic Retinopathy Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Diabetic Retinopathy Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Diabetic Retinopathy Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Diabetic Retinopathy Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Diabetic Retinopathy Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Diabetic Retinopathy Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Diabetic Retinopathy Treatment and Management
8.2. Diabetic Retinopathy Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Diabetic Retinopathy Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Diabetic Retinopathy : Seven Major Market Analysis
13.1. Key Findings
13.2. Diabetic Retinopathy Market Size in 7MM
13.3. Diabetic Retinopathy Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Diabetic Retinopathy Total Market Size in the United States
15.1.2. Diabetic Retinopathy Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Diabetic Retinopathy Total Market Size in Germany
15.3.2. Diabetic Retinopathy Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Diabetic Retinopathy Total Market Size in France
15.4.2. Diabetic Retinopathy Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Diabetic Retinopathy Total Market Size in Italy
15.5.2. Diabetic Retinopathy Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Diabetic Retinopathy Total Market Size in Spain
15.6.2. Diabetic Retinopathy Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Diabetic Retinopathy Total Market Size in the United Kingdom
15.7.2. Diabetic Retinopathy Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Diabetic Retinopathy Total Market Size in Japan
15.8.3. Diabetic Retinopathy Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Diabetic Retinopathy
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
List of Table
Table 1: Risk Factors
Table 2: Genetic polymorphisms and diabetic retinopathy
Table 3: Total cases of Diabetic Retinopathy in 7MM (2017–2030)
Table 4: Total Diagnosed cases of Diabetic Retinopathy in the United States (2017–2030)
Table 5: Gender-specific cases of Diabetic Retinopathy in the US (2017–2030)
Table 6: Age-specific cases of Diabetic Retinopathy in the US (2017–2030)
Table 7: Severity-specific cases of Diabetic Retinopathy in the US (2017–2030)
Table 8: Total Diagnosed cases of Diabetic Retinopathy in Germany (2017–2030)
Table 9: Gender-specific cases of Diabetic Retinopathy in Germany (2017–2030)
Table 10: Age-specific cases of Diabetic Retinopathy in Germany (2017–2030)
Table 11: Severity-specific cases of Diabetic Retinopathy in Germany (2017–2030)
Table 12: Total Diagnosed cases of Diabetic Retinopathy in France (2017–2030)
Table 13: Gender-specific cases of Diabetic Retinopathy in France (2017–2030)
Table 14: Age-specific cases of Diabetic Retinopathy in France (2017–2030)
Table 15: Severity-specific cases of Diabetic Retinopathy in France (2017–2030)
Table 16: Total Diagnosed cases of Diabetic Retinopathy in Italy (2017–2030)
Table 17: Gender-specific cases of Diabetic Retinopathy in Italy (2017–2030)
Table 18: Age-specific cases of Diabetic Retinopathy in Italy (2017–2030)
Table 19: Severity-specific cases of Diabetic Retinopathy in Italy (2017–2030)
Table 20: Total Diagnosed cases of Diabetic Retinopathy in Spain (2017–2030)
Table 21: Gender-specific cases of Diabetic Retinopathy in Spain (2017–2030)
Table 22: Age-specific cases of Diabetic Retinopathy in Spain (2017–2030)
Table 23: Severity-specific cases of Diabetic Retinopathy in Spain (2017–2030)
Table 24: Total Diagnosed cases of Diabetic Retinopathy in the United Kingdom (2017–2030)
Table 25: Gender-specific cases of Diabetic Retinopathy in the UK (2017–2030)
Table 26: Age-specific cases of Diabetic Retinopathy in the UK (2017–2030)
Table 27: Severity-specific cases of Diabetic Retinopathy in the UK (2017–2030)
Table 28: Total Diagnosed cases of Diabetic Retinopathy in Japan (2017–2030)
Table 29: Gender-specific cases of Diabetic Retinopathy in Japan (2017–2030)
Table 30: Age-specific cases of Diabetic Retinopathy in Japan (2017–2030)
Table 31: Severity-specific cases of Diabetic Retinopathy in Japan (2017–2030)
Table 32: LUCENTIS, Clinical Trial Description, 2020
Table 33: EYLEA, Clinical Trial Description, 2020
Table 34: Brolucizumab, Clinical Trial Description, 2020
Table 35: Faricimab, Clinical Trial Description, 2020
Table 36: ADVM 022, Clinical Trial Description, 2020
Table 37: BI 1467335, Clinical Trial Description, 2020
Table 38: GB-102, Clinical Trial Description, 2020
Table 39: Emixustat Hydrochloride, Clinical Trial Description, 2020
Table 40: KVD001, Clinical Trial Description, 2020
Table 41: LKA651, Clinical Trial Description, 2020
Table 42: Luminate, Clinical Trial Description, 2020
Table 43: RG7774, Clinical Trial Description, 2020
Table 44: BI 764524, Clinical Trial Description, 2020
Table 45: Market Size of Diabetic Retinopathy in 7MM in USD Million (2017–2030)
Table 32: US Market Size of Diabetic Retinopathy in USD Million (2017–2030)
Table 47: US Market Size of Diabetic Retinopathy in USD Million (2017–2030)
Table 48: Market Size of Diabetic Retinopathy in Germany, USD Millions (2017–2030)
Table 49: Germany Market Size of Diabetic Retinopathy in USD Million (2017–2030)
Table 50: Market Size of Diabetic Retinopathy associated in France, USD Millions (2017–2030)
Table 51: France Market Size of Diabetic Retinopathy in USD Million (2017–2030)
Table 52: Market Size of Diabetic Retinopathy in Italy, USD Millions (2017–2030)
Table 53: Italy Market Size of Diabetic Retinopathy in USD Million (2017–2030)
Table 54: Market Size of Diabetic Retinopathy in Spain, USD Millions (2017–2030)
Table 55: Spain Market Size of Diabetic Retinopathy in USD Million (2017–2030)
Table 56: Market Size of Diabetic Retinopathy in the UK, USD Millions (2017–2030)
Table 57: UK Market Size of Diabetic Retinopathy in USD Million (2017–2030)
Table 58: Market Size of Diabetic Retinopathy in Japan, USD Millions (2017–2030)
Table 59: Japan Market Size of Diabetic Retinopathy in USD Million (2017–2030)
List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Pathways involved in Diabetic Retinopathy
Figure 3: Risk factors for Diabetic retinopathy.
Figure 4: Total cases of Diabetic Retinopathy in 7MM (2017–2030)
Figure 5: Total Diagnosed cases of Diabetic Retinopathy in the United States (2017–2030)
Figure 6: Gender-Specific cases of Diabetic Retinopathy in the US (2017–2030)
Figure 7: Age-specific cases of Diabetic Retinopathy in the US (2017–2030)
Figure 8: Severity-specific cases of Diabetic Retinopathy in the US (2017–2030)
Figure 9: Total Diagnosed cases of Diabetic Retinopathy in Germany (2017–2030)
Figure 10: Gender-Specific cases of Diabetic Retinopathy in Germany (2017–2030)
Figure 11: Age-specific cases of Diabetic Retinopathy in Germany (2017–2030)
Figure 12: Severity-specific cases of Diabetic Retinopathy in Germany (2017–2030)
Figure 13: Total Diagnosed cases of Diabetic Retinopathy in France (2017–2030)
Figure 14: Gender-Specific cases of Diabetic Retinopathy in France (2017–2030)
Figure 15: Age-specific cases of Diabetic Retinopathy in France (2017–2030)
Figure 16: Severity-specific cases of Diabetic Retinopathy in France (2017–2030)
Figure 17: Total Diagnosed cases of Diabetic Retinopathy in Italy (2017–2030)
Figure 18: Gender-Specific cases of Diabetic Retinopathy in Italy (2017–2030)
Figure 19: Age-specific cases of Diabetic Retinopathy in Italy (2017–2030)
Figure 20: Severity-specific cases of Diabetic Retinopathy in Italy (2017–2030)
Figure 21: Total Diagnosed cases of Diabetic Retinopathy in Spain (2017–2030)
Figure 22: Gender-Specific cases of Diabetic Retinopathy in Spain (2017–2030)
Figure 23: Age-specific cases of Diabetic Retinopathy in Spain (2017–2030)
Figure 24: Severity-specific cases of Diabetic Retinopathy in Spain (2017–2030)
Figure 25: Total Diagnosed cases of Diabetic Retinopathy in the United Kingdom (2017–2030)
Figure 26: Gender-Specific cases of Diabetic Retinopathy in the UK (2017–2030)
Figure 27: Age-specific cases of Diabetic Retinopathy in the UK (2017–2030)
Figure 28: Severity-specific cases of Diabetic Retinopathy in the UK (2017–2030)
Figure 29: Total Diagnosed cases of Diabetic Retinopathy in Japan (2017–2030)
Figure 30: Gender-Specific cases of Diabetic Retinopathy in Japan (2017–2030)
Figure 31: Age-specific cases of Diabetic Retinopathy in Japan (2017–2030)
Figure 32: Severity-specific cases of Diabetic Retinopathy in Japan (2017–2030)
Figure 33: Treatment guidelines by the American Academy of Ophthalmology
Figure 34: Unmet Needs
Figure 35: Market Size of Diabetic Retinopathy in USD Million (2017–2030)
Figure 36: Market Size of Diabetic Retinopathy in the US, USD Millions (2017–2030)
Figure 37: Market Size of Diabetic Retinopathy in the US by therapies, USD Millions (2017–2030)
Figure 38: Market Size of Diabetic Retinopathy in Germany, USD Millions (2017–2030)
Figure 39: Market Size of Diabetic Retinopathy in Germany by therapies, USD Millions (2017–2030)
Figure 40: Market Size of Diabetic Retinopathy in France, USD Millions (2017–2030)
Figure 41: Market Size of Diabetic Retinopathy in France by therapies, USD Millions (2017–2030)
Figure 42: Market Size of Diabetic Retinopathy in Italy, USD Millions (2017–2030)
Figure 43: Market Size of Diabetic Retinopathy in Italy by therapies, USD Millions (2017–2030)
Figure 44: Market Size of Diabetic Retinopathy in Spain, USD Millions (2017–2030)
Figure 45: Market Size of Diabetic Retinopathy in Spain by therapies, USD Millions (2017–2030)
Figure 46: Market Size of Diabetic Retinopathy in the UK, USD Millions (2017–2030)
Figure 47: Market Size of Diabetic Retinopathy in the UK by therapies, USD Millions (2017–2030)
Figure 48: Market Size of Diabetic Retinopathy in Japan, USD Millions (2017–2030)
Figure 49: Market Size of Diabetic Retinopathy in Japan by therapies, USD Millions (2017–2030)
Figure 50: Market Drivers
Figure 51: Market Barriers
Genentech
Regeneron Pharmaceuticals
Novartis Pharmaceuticals
Roche
Adverum Biotechnologies Inc.
Boehringer Ingelheim
Graybug Vision
Kubota Vision Inc.
KalVista Pharmaceuticals Ltd.
Allegro Ophthalmics LLC
Roche
Boehringer Ingelheim
